Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Low Dose IL-2 for the Treatment of Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04263831
Recruitment Status : Recruiting
First Posted : February 11, 2020
Last Update Posted : May 20, 2022
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Scott B. Snapper, MD PHD, Boston Children's Hospital

Brief Summary:
The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.

Condition or disease Intervention/treatment Phase
Crohn Disease Drug: Interleukin-2 (aldesleukin). Phase 1 Phase 2

Detailed Description:

Despite recent advances in treatment, a significant proportion of patients with Crohn's disease have suboptimal responses to medical therapy, leaving an urgent need to identify new therapies. One promising new approach to trea t IBD is through the manipulation of regulatory T cells (Tregs). Tregs are an immune modulating subset of CD4+ lymphocytes that antagonize the activation and effector function of multiple immune cell types and promote tolerance to self-antigens. Adoptively transferred Tregs are effective in murine models of IBD. An alternative approach to disease management through Treg manipulation is to increase Treg numbers in vivo. Interleukin-2 (IL-2, Proleukin®) is a T cell growth factor. IL-2 is currently licensed for the treatment of metastatic renal cell carcinoma and metastatic melanoma. At low doses, IL-2 promotes the selective activation and expansion of Tregs in humans. Tregs constitutively express CD25, a component of the high-affinity IL-2R, while CD25 is only transiently expressed by activated conventional T effector cells. Low-dose (LD) IL-2 selectively expands Tregs in humans and is safe in chronic GvHD and other phase 1 and 2 clinical trials.

This is a phase 1b/2a clinical trial to assess the safety and the efficacy of LD SC IL-2 for the treatment of CD utlizing daily sc LD IL-2 for 8 weeks in CD patients to determine the maximum effective dose (MED) and safety profile, and to assess a signal of efficacy. We aim to determine in CD patients whether sc LD IL-2 modulates peripheral blood and lamina propria Tregs in vivo and correlates with clinical outcome. We will perform deep immunophenotyping in CD patients treated with LD IL-2 and comprehensively assess the effects of LD IL-2 on CD4+ Tregs and other immune cells in both peripheral and mucosal compartments, and correlate changes in immune phenotype with clinical outcome. Overall this trial is designed to determine the MED and safety profile of LD IL-2 in CD, to obtain a signal of efficacy, and to assess mechanistic underpinnings.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Low Dose IL-2 for the Treatment of Crohn's Disease
Actual Study Start Date : March 11, 2021
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : December 31, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease
Drug Information available for: Aldesleukin

Arm Intervention/treatment
Experimental: Interleukin-2

Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).

Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be two dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.

The dose levels will be as follows:

Cohort 1: 1.0x10^6 IU/m^2/day. Cohort 2: 1.25x10^6 IU/m^2/day.

Drug: Interleukin-2 (aldesleukin).
Description of intervention is covered in "Arm", above.

Primary Outcome Measures :
  1. Number of subjects with serious and non-serious adverse events. [ Time Frame: 8 weeks ]
    Enumeration of the serious and non-serious adverse events seen in the study. Enumeration of any dose limiting toxicity seen in the study.

  2. Maximum effective dose [ Time Frame: 8 weeks ]
    Identification of the dose cohort at which the MED occurs.

Secondary Outcome Measures :
  1. Clinical Response [ Time Frame: 8 weeks ]

    This is a composite endpoint. CDAI scores will be used to assess clinical activity. Moderate to severe CD, denoted by a CDAI score 220-450, is an inclusion criterion.

    Definition of Clinical Response. CDAI-100 response (≥100-point decrease in the CDAI score) at week 8 Composite Outcome: Clinical response and atleast a 50% decrease in fecal calprotectin or CRP

  2. Immunological Response [ Time Frame: 12 weeks ]
    Enumeration of the number of subjects with a change in the absolute number of immune cells in the peripheral blood and lamina propria of subjects during the 8 weeks of treatment, and during the 4 weeks following cessation of treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18-80 years. Maximum age limit for subjects recruited at BCH will be 30 years.
  2. A diagnosis of CD made by standard clinical, radiological, endoscopic and histological criteria.

    a. A subset of patients with Ileostomies or colostomies will be permitted.

  3. Adult subjects with moderate-to-severe CD (CDAI score 220-450)

    a. a modified CDAI will be used to assess patients with ileostomies/colostomies. Number of liquid stools per day will be substituted for number of bag empties per day.

  4. Evidence of endoscopic inflammation accessible via ileocolonoscopy or ileoscopy

    1. Simple Endoscopic Score for CD (SES-CD) ≥ 6 or ≥ 4 for isolated ileal disease
    2. patients with ileostomies will be assessed as patients with isolated ileal disease via SES-CD.
  5. Failure to tolerate or failure to respond to at least one conventional therapy with the intention of inducing or maintaining remission (including but not limited to oral corticosteroids, oral 5-aminosalicylates, azathioprine and/or 6-mercaptopurine, TNF alpha antagonist, anti-integrins, ustekinumab). Corticosteroid dependency (inability to taper oral corticosteroids without a recurrence of disease activity) is also included in this category.
  6. Stable doses of concomitant medications, as defined in Section 5
  7. A negative pregnancy test within 2 weeks prior to anticipated commencement of the study drug, in female subjects of child-bearing age. Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment.
  8. The ability of adult participants who are able to make their own healthcare decisions to provide informed consent or the ability of a legal guardian to provide consent if the participant has mild intellectual disability and cannot consent for him or herself. In the event that a legal guardian provides consent, the study participant must be able to demonstrate an understanding of the study at his or her comprehension level and must have the ability to give verbal assent. The legal guardian must be able to provide documentation of court appointed guardianship.

Exclusion Criteria:

  1. A diagnosis of ulcerative colitis or indeterminate colitis.
  2. Requirement for immediate surgical, endoscopic or radiological intervention for perforation, sepsis, or intra-abdominal or perianal abscess.
  3. History of colorectal cancer or dysplasia.
  4. Positive stool test for Clostridium difficile via GDH/EIA two step testing method. PCR only testing will not be accepted. If patient is GDH positive and EIA negative, enrollment will be permitted.
  5. Current medically significant infection.
  6. Significant laboratory abnormalities;

    1. Hb < 7.0 g/dL, WBC < 2.5 x 103/mm3, Plt < 50 x 103/mm3.
    2. Creatinine ≥ 2x institutional ULN.
    3. Total bilirubin > 2.0 mg/dL, ALT > 2x institutional ULN. Elevated unconjugated bilirubin related to Gilbert's syndrome is allowed.
    4. Abnormal thyroid function tests.
  7. Positive serology for HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV).
  8. Positive screening test for tuberculosis (TB).
  9. Treatment with any biologic medication within 4 weeks of first study drug dose (baseline) (see below section on washouts)
  10. Received another IND within 5 half-lives of that agent baseline.
  11. Malignancy within the last 5 years, excluding non-melanoma skin cancer.
  12. Allergy to any component of the study drug.
  13. Pregnant or lactating women.
  14. Inability to comply with the study protocol or inability of the subject or the subject's legal guardian to provide informed consent.
  15. Prior exposure to IL-2.
  16. Uncontrolled cardiac angina or symptomatic congestive cardiac failure (NYHA Class III or IV).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04263831

Layout table for location contacts
Contact: Jennifer J Mitri 617-525-7322
Contact: Gwen O Saccocia 617-919-4592

Layout table for location information
United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Gwen O Saccocia    617-919-4592   
Contact: Richelle L Bearup, MPH    617-919-4592   
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Jennifer J Mitri    617-525-7322   
United States, New York
Mount Sinai Recruiting
New York, New York, United States, 10029
Contact: Sari Feldman    212-824-7669   
Principal Investigator: Jean Fred Colombel, MD         
Sponsors and Collaborators
Boston Children's Hospital
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Layout table for investigator information
Principal Investigator: Scott Snapper, MD, PhD Boston Children's Hospital
Principal Investigator: Jessica Allegretti, MD, MPH Brigham and Women's Hosptial

Layout table for additonal information
Responsible Party: Scott B. Snapper, MD PHD, Chief, Gastroenterology, Boston Children's Hospital Identifier: NCT04263831    
Other Study ID Numbers: IRB-P00032653
R01DK126448 ( U.S. NIH Grant/Contract )
First Posted: February 11, 2020    Key Record Dates
Last Update Posted: May 20, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Scott B. Snapper, MD PHD, Boston Children's Hospital:
Inflammatory bowel disease
Interleukin 2
Regulatory T Cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Antineoplastic Agents
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents